DermBiont, Inc.

DermBiont, Inc. is a United States-based dermatology-focused biotechnology company headquartered in Boston, Massachusetts. The company is developing a pipeline of topical therapeutics aimed at skin pigmentation disorders, with its lead candidate SM-030 positioned as a potential first-in-class treatment for melasma and other hyperpigmentation conditions. According to the company's official website, DermBiont is advancing SM-030 as a novel topical PKC-beta inhibitor. The company describes SM-030 as a first-in-class product with a well-defined mechanism of action and states that it is the first product intended to address the root cause of hyperpigmentation. The company's stated goal is to deliver the first safe and effective daily topical treatment for melasma. DermBiont operates in the biotechnology sector, specifically within dermatology and skin health. Its focus on melasma and hyperpigmentation places it in a segment of dermatology where effective, well-tolerated daily topical therapies remain limited. The company is privately held and, as of available public information, is headquartered in Boston, United States. Beyond its lead program, DermBiont's public communications emphasize a science-driven approach to skin pigmentation, targeting the underlying biology of hyperpigmentation rather than only addressing surface symptoms. The company's website highlights the clinical advancement of SM-030 and its potential to become a standard-of-care topical option for patients with melasma.

DermBiont, Inc. is a privately held biotechnology company based in Boston, Massachusetts, United States. The company is focused on developing topical therapeutics for dermatological conditions, with a lead program in skin pigmentation disorders. DermBiont's public communications center on SM-030, a novel topical PKC-beta inhibitor being advanced for the treatment of melasma and hyperpigmentation disorders of the skin. According to the company's website, SM-030 is a first-in-class product with a well-defined mechanism of action and is described as the first product to address the root cause of hyperpigmentation. The company states that it is delivering the first safe and effective daily topical for the treatment of melasma. The company is headquartered in Boston, United States, according to Wikidata. As a clinical-stage company, DermBiont's activities are primarily directed toward research and development of its pipeline rather than commercialized products. No specific founding date, founder names, or ownership details are available in the provided evidence.

Clinical-stage dermatology biotechnology company developing first-in-class topical therapies for skin pigmentation disorders.

• SM-030

  A novel topical PKC-beta inhibitor being advanced for the treatment of melasma and hyperpigmentation disorders of the skin. Described as a first-in-class product with a well-defined mechanism of action and the first product to address the root cause of hyperpigmentation.

• 2020.10.21

  Reported2020.10.21

  DermBiont acquires SeylanMED[4]DermBiont收购SeylanMEDprweb.com

  DermBiont acquired SeylanMED, expanding its therapeutic pipeline and modalities.

Read more

1. 1DermBiontdermbiont.com
2. 2Overview — DermBiontdermbiont.com
3. 3DermBiont, Inc. (United States) — Wikidatawikidata.org
4. 4DermBiont收购SeylanMEDprweb.com